Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129080 | 0.86 | DGAT1 (0.52) | DGAT1LPLLIPG | |
| SCHEMBL31409564 | 0.85 | MAOB (0.53) | MAOBDGAT1LPLLIPGPTPN1 | |
| SCHEMBL17129613 | 0.85 | MAOB (0.59) | MAOBDGAT1FFAR1MAOA | |
| SCHEMBL21568905 | 0.85 | LPL (0.59) | MAOBDGAT1LPLLIPG | |
| SCHEMBL19000509 | 0.84 | DGAT1 (0.50) | DGAT1LPLLIPG | |
| SCHEMBL19000571 | 0.83 | DGAT1 (0.57) | DGAT1LPLLIPG | |
| SCHEMBL17129607 | 0.83 | DGAT1 (0.56) | MAOBDGAT1LPLLIPG | |
| SCHEMBL21234416 | 0.83 | DGAT1 (0.56) | MAOBDGAT1LPLLIPG | |
| SCHEMBL2267580 | 0.83 | DGAT1 (0.56) | MAOBDGAT1LPLLIPG | |
| SCHEMBL805968 | 0.83 | CA1 (0.49) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124534-B | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application | 中山大学 | 2023-09-15 | — | — | CN | disclosed |
| EP-3569602-B1 | IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | DONGGUAN ZHENGXING BEITE MEDICINE TECH CO LTD (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-115124534-A | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application | 中山大学 | 2022-09-30 | — | — | CN | disclosed |
| US-10919899-B2 | Imidazopyrazine compounds, preparation methods and uses thereof | DONGGUAN ZHENXING-BEITE MEDICINE TECHNOLOGY CO., LTD. (CN) | 2021-02-16 | — | — | US | disclosed |
| EP-3569602-A1 | IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Dongguan Zhengxing-Beite Medicine Technology Co., Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-07 | — | — | US | disclosed |
| CN-106588937-B | Imidazopyrazines and its preparation method and application | 东莞市真兴贝特医药技术有限公司 | 2018-09-21 | — | — | CN | disclosed |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| CN-106588937-A | Imidazopyrazine compound, and preparation method and application thereof | 东莞市真兴贝特医药技术有限公司 | 2017-04-26 | — | — | CN | disclosed |
| WO-2015144799-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919899-B2 | Imidazopyrazine compounds, preparation methods and uses thereof | BTK, SYK, ABL1 | MAOB 1027/4885DGAT1 4572/4885LPL 3295/4885 |
| US-10280170-B2 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | ROS1, NOX1, NOX5 | MAOB 1222/4885DGAT1 2213/4885LPL 4314/4885 |
| US-20170174690-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | ROS1, NOX1, NOX5 | MAOB 1222/4885DGAT1 2213/4885LPL 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.